Literature DB >> 8494545

Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.

D Y Bouffard1, J Laliberté, R L Momparler.   

Abstract

Phosphorylation of cytosine analogs by deoxycytidine kinase (dCK) and deamination by cytidine deaminase (CDA) are two important processes in the activation and elimination of these drugs. We have investigated the kinetic parameters of 2',2'-difluorodeoxycytidine (dFdC) using purified enzymes from human cells. Deoxycytidine (CdR) and dFdC had Km values of 1.5 and 4.6 microM for dCK, respectively. Feedback inhibition of dCK by deoxycytidine 5'-triphosphate (dCTP) was also studied. Our results show that dCTP produced a greater inhibition of the phosphorylation of dFdC than CdR with concentrations of dCTP ranging from 1 to 25 microM. dFdC was a good substrate for CDA. Kinetic studies with this enzyme gave Km values for CdR and dFdC of 46.3 and 95.7 microM, respectively. The effect of competitive inhibitors of CDA on the deamination of dFdC was also investigated. Diazepinone riboside was a more potent inhibitor than tetrahydrouridine using either CdR or dFdC as the substrate. Inhibitors of CDA could be useful in clinical trials in patients with cancer to increase the chemotherapeutic effectiveness of dFdC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494545     DOI: 10.1016/0006-2952(93)90444-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  37 in total

1.  Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.

Authors:  Valeria Sebastiani; Francesca Ricci; Belen Rubio-Viqueira; Belen Rubio-Viquiera; Piotr Kulesza; Charles J Yeo; Manuel Hidalgo; Alison Klein; Daniel Laheru; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.

Authors:  Milena Gusella; Felice Pasini; Caterina Bolzonella; Silvia Meneghetti; Carmen Barile; Antonio Bononi; Silvia Toso; Daniela Menon; Giorgio Crepaldi; Yasmina Modena; Laura Stievano; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

3.  Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.

Authors:  Hongmei Ruan; Songbo Qiu; Brian C Beard; Margaret E Black
Journal:  Protein Eng Des Sel       Date:  2016-05-08       Impact factor: 1.650

4.  Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.

Authors:  Soukaina Réjiba; Christelle Bigand; Céline Parmentier; Amor Hajri
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

5.  Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.

Authors:  Dharmika S P Lansakara-P; B Leticia Rodriguez; Zhengrong Cui
Journal:  Int J Pharm       Date:  2012-03-16       Impact factor: 5.875

6.  Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.

Authors:  Xu Zhu; Sheryl Trueman; Robert M Straubinger; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-08-01       Impact factor: 2.745

7.  Gemcitabine-vitamin E conjugates: Synthesis, characterization, entrapment into nanoemulsions, and in-vitro deamination and antitumor activity.

Authors:  Ahmed Abu-Fayyad; Sami Nazzal
Journal:  Int J Pharm       Date:  2017-06-13       Impact factor: 5.875

8.  dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.

Authors:  Florencia McAllister; Danielle M Pineda; Masaya Jimbo; Shruti Lal; Richard A Burkhart; Jennifer Moughan; Kathryn A Winter; Kotb Abdelmohsen; Myriam Gorospe; Ana de Jesus Acosta; Rachana H Lankapalli; Jordan M Winter; Charles J Yeo; Agnieska K Witkiewicz; Christine A Iacobuzio-Donahue; Daniel Laheru; Jonathan R Brody
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

9.  Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.

Authors:  S F Dent; A Arnold; D J Stewart; S Gertler; J Ayoub; G Batist; G Goss; A Nevile; D Soulieres; J Jolivet; L McLntosh; L Seymour
Journal:  Lung       Date:  2005 Jul-Aug       Impact factor: 2.584

10.  Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.

Authors:  Agnes Juhasz; Paul Frankel; Catherine Cheng; Hector Rivera; Reena Vishwanath; Alice Chiu; Kim Margolin; Yun Yen; Edward M Newman; Tim Synold; Sharon Wilczynski; Heinz-Josef Lenz; David Gandara; Kathy S Albain; Jeffrey Longmate; James H Doroshow
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.